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Introduction
Glycosylation refers to the enzymatic post-translational modification 
in which the addition of complex oligosaccharide molecules (glycans) 
enriches protein complexity and functional diversity [1]. Glycans have a 
broad spectrum of biological roles, including their influence on protein 
folding, cell signaling and immune function [2]. Alongside the genome 
and proteome, the human glycome is subject to immense variation [3]. 
This variation arises as the reactions that link individual sugar units 
together are influenced heavily by several factors, both genetic and 
environmental, including cell metabolism, genomic enzyme expression 
and nutrient availability [4]. N-glycosylation, in which the glycan is 
linked with nitrogen of asparagine or arginine side-chains, is the most 
common type of glycosidic bond. N-glycan profiles have been found 
to remain highly stable over periods of time, with even up to one year 
between measurements [5]. This suggests that alterations to human 
N-glycan profiles may be due to pathophysiological mechanisms or 
complex environmental exposures.
Recent advances in high throughput analytical technology, 
including High Performance Liquid Chromatography (HPLC), have 
fueled a growing interest in the role of glycans in health and disease 
[6]. Glycans have already been implicated in the pathology of numerous 
inflammatory disorders, including inflammatory bowel disease, various 
cancers and rheumatoid arthritis [3,7]. 
Metabolic Syndrome (MetS) is defined as a cluster of biochemical 
and physiological characteristics including hypertension, central 
obesity, hyperglycemia and dyslipidemia [8]. This syndrome is a global 
epidemic, which sets the scene for Type 2 Diabetes Mellitus (T2DM) and 
its microvascular complications, alongside hastening the progression of 
macrovascular pathologies. On a global scale the prevalence of MetS is 
rising, hence there is a growing interest in investigating the alterations 
in metabolism which are involved in pathophysiological processes 
underlying this syndrome.
  Our current understanding of the cardiovascular and metabolic 
pathways associated with this syndrome presents a complex array of 
pathological alterations which contribute to endothelial dysfunction, 
plaque formation and increased thrombotic potential. It has been 
demonstrated that the increased levels of angiotensin II associated 
with high blood pressure leads to the activation of many atherogenic 
processes including the promotion of monocyte adhesion through the 
increased expression of adhesion molecules [9,10]. Angiotensin II is also 
known to increase oxidative stress, thrombosis and vasoconstriction 
[11], whilst several of the adipokines produced in adipose tissue have 
been found to also have a role in these pathways. The adipokine tumor 
necrosis factor alpha has been found to contribute to insulin resistance 
whilst increased circulating levels of PAI-1 have been linked to the 
heightened thrombotic state found in obesity [12,13]. 
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Abstract
Background: Alterations in glycosylation patterns have long been known to reflect changes in cell metabolism. In this 
study, we investigated the relationship between human N-glycan profiles and metabolic syndrome.
Method: Between 2005 and 2011, 2,155 individuals from the Orkney Islands (UK) were recruited and biological 
material, alongside phenotypic measures were collected. Individual N-glycan profiles were measured in plasma using weak 
anion exchange high performance liquid chromatography and calibrated hydrophilic interaction liquid chromatography. 
Pre-specified criteria were used to identify 564 cases with metabolic syndrome and 1475 controls. We applied logistic 
regression to test for association between this binary outcome against measured plasma N-glycans. We also assessed 
the correlation between N-glycan traits and individual components of metabolic syndrome and compared this to results 
found in similar analyses based in Chinese and Croatian populations. 
Results: 21 N-glycan traits were found to be associated with either an increased or a decreased likelihood of 
participants having metabolic syndrome, including monosialylated plasma N-glycans (OR of 1.49 (95%CI 1.33, 1.67), 
q=1.26E-12) and core fucosylated plasma N-glycans (OR of 0.81(95% CI 0.72-0.90), q=7.75E-4). Notably, consistent 
results in both sections of this analysis demonstrated the protective association of higher levels of core fucosylated 
N-glycans.
Conclusion: Our results demonstrate that metabolic syndrome is associated with an alteration in plasma 
N-glycosylation patterns. The metabolic role of core fucosylated N-glycans is of particular interest for future study.
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It is thought that insulin resistance also contributes to the classic 
scenario of endothelial dysfunction and vascular inflammation. 
Alongside its effect on free fatty acids, insulin insensitivity causes an 
impairment of the Phosphatidylinositol-3-kinase pathway (PI-3K), 
which ensures it’s anti-inflammatory and vasodilatory effects are 
ceased. Alongside this, insulin resistance leads to an amplification 
of the mitogen-activated protein kinase pathway, thus leading to 
increased production of pro-inflammatory molecules like vascular 
cellular adhesion molecule-1 and an increased demand for extracellular 
matrix production [14]. It is thought that such pathways contribute 
to the classic pathological scenario of endothelial dysfunction 
and vascular inflammation. Importantly, it is understood that the 
vascular complications associated with insulin resistance begin before 
hyperglycaemia is evident in the clinical setting, thus the identification 
of risk earlier in these patients may be key in providing targeted 
interventions.
It is evident that the role of glycosylation in the alterations of cell-
cell interactions and signaling may be an important area of study. As 
many of the pathways associated with MetS involve the production of 
inflammatory cells, glycosylation profiles may prove to be important in 
providing insight into the metabolic state of productive cells. There is 
also potential for glycosylation profiles to be useful in identifying those 
at increased risk of the pathologies associated with MetS, alongside 
potentially identifying those who have subclinical levels of insulin 
resistance and atherosclerotic disease. Thus it is evident that the many 
metabolic changes present in MetS may ensure individuals present with 
a complex array of N-glycosylation alterations. 
The first and only attempt to date at screening for novel glycomic 
biomarkers for MetS was undertaken by Lu et al. in Chinese and 
Croatian populations [15]. This study successfully identified several 
glycan traits which were found to be correlated both in the negative 
and positive direction with MetS components. Alongside the small 
population size used in this study (n=212), multiple testing limited 
the interpretation of the results of this hypothesis generating analysis. 
In addition, the phenotypic characteristics measured did not cover all 
components of MetS, lacking measures of lipid levels, waist size and 
medication use. 
The Orkney Complex Disease Study (ORCADES) is a large-scale 
genetic epidemiology study which completed the recruitment of 
over 2000 individuals in March 2011 [16]. We utilised this study to 
investigate the associations between components of the MetS and 46 
whole plasma N-glycan components. Thus, it is the aim of this study to 
identify associations between N-glycans and MetS and to also compare 
results found in an Orcadian population to results found in Chinese 
and Croatian populations.
Materials and Methods
Study populations 
ORCADES study recruitment procedures and methods: 
Individuals with ancestry from the North Isles of Orkney were recruited 
between 2005 and 2011 to participate in the Orkney Complex Disease 
Study (ORCADES). Means of recruitment included advertisements 
in local media, posters, talks with local organisations and community 
leaders, alongside obtaining details from other eligible persons through 
contact with volunteers. The resultant sample was 40% male and included 
over 2,000 individuals with an age range of 18-91 years, with a median 
age of 54 [16]. Participants were interviewed by a trained practitioner 
regarding demographic characteristics and questionnaires regarding 
lifestyle, environmental exposures and medical history were completed. 
Body weight, height and waist measurements were obtained during the 
physical examination by a trained practitioner. Blood pressure readings 
were taken twice, minutes apart. Blood samples for glycan, lipid and 
and Fasting Plasma Glucose (FPG) analysis were collected following 
overnight fasting in test tubes containing Ethylennediaminetetraacetic 
acid (EDTA) anticoagulant. Samples were then processed immediately 
and plasma was removed from whole blood and stored at -70°C until 
further analysis.
Recruitment procedures and methods for study based in Chinese 
population 
As reported in Lu et al. 310 participants were selected for recruitment 
from a hospital in Beijing (Xuanwu Hospital) whilst undergoing routine 
health check-ups between April and July 2009. Individuals who had a 
history of mental or physical illness, alongside those who had taken any 
medications in the previous two weeks were excluded, thus 212 healthy 
volunteers were recruited. The resulting sample was 46.7% male, with 
an age range of 18-89 years and a mean age of 37.8 years [15].
Physical examinations and interviews of participants were carried 
out by trained nurses and physicians. During these, height, weight and 
BP were measured (two BP readings, 5 minutes apart). Alongside this, 
fasting blood samples (5 mL) were obtained after a 12 h overnight fast 
in a vacuum negative pressure tube containing EDTA, for FPG measure 
and glycan analysis. Samples were then stored at 4°C, before plasma 
samples were obtained for glycan analysis by centrifugation at 3000rpm 
for 10 min and were then stored at - 80°C until analysis.
Recruitment procedures and methods for study based in 
Croatian population
As part of a large genetic epidemiology program participants were 
recruited between 2003 and 2004 on the Croatian island of Vis and 
during 2007 on the island of Knežević [17]. Recruitment procedures 
included the use of voting registers, contact with local stakeholders and 
religious organisations. In total, 1991 individuals were recruited, whilst 
only 520 unrelated participants were used in the analysis.
Trained practitioners measured physical characteristics including 
many body fat estimation methods such as BMI, bioelectrical 
impedance, waist measurements and skinfold thickness. Blood pressure 
was recorded as the average of two independent measurements, whilst 
blood samples for lipid, FPG, glycan and many more characteristics 
analysis were taken after overnight fasting in tubes containing 
anticoagulant. Plasma samples were then immediately separated and 
stored at -70°C.
Ethics statement 
All participants provided written informed consent and the 
included studies received ethical approval from the approved by their 
respective ethical committees. This included the NHS Orkney Research 
Ethics Committee, North of Scotland Research Ethics Committee and 
the Ethics Committee of the Medical School, University of Split. This 
project also gained ethical approval from The University of Edinburgh’s 
Centre for Population Health Sciences Research Ethics Subgroup.
Glycan analysis
N-glycans from the plasma samples were released and labelled 
through exoglycosidase digestion and 2-aminobenzamide respectively, 
as described previously [6]. A centrifuge was then used to dry 
glycans before redissolving them in a known volume of water for 
further analysis. The weak anion exchange high performance liquid 
chromatography (WAX-HPLC) method was used in order to separate 
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the plasma N-glycome into 4 groups according to number of sialic acids 
(monosialylated, disialylated, trisialylated and tetrasialylated).
Hydrophilic interaction High-Performance Chromatography 
(HILIC), calibrated by an external standard of hydrolyzed and 2-AB-
labeled glucose oligomers, was then used to analyse the prepared 
samples. As displayed above, this chromatographic analysis separated 
the plasma N-glycome into 16 groups (GP1-GP16). As a quality control 
measure to check for the effect of the batch process, duplicate analysis 
of several of the samples was performed and this measure confirmed 
the reproducibility of the results. See McQuillan et al. [16] for a more 
detailed description of methods. 
After this, in order to improve the precision of analysis, sialidase 
digestion was performed [18]. This involved drying the samples once 
more before adding sodium acetate incubation buffer, arthrobacter 
ureafaciens sialidase enzyme and water to aliquots. After overnight 
incubation, samples were then passed through a Micropure-EZ enzyme 
remover enzyme remover. HILIC analysis of these samples separated 
the plasma N-glycan profiles into 13 groups of desialylated glycans 
(DG1-DG13). Derived glycan measures, according to structural 
features were then calculated. 
Statistical analysis 
Prior to analysis, due to the non-parametric nature of glycan 
measurement distribution, glycan measurements were rank 
transformed. Graphs of the distributions of continuous measurements 
were then assessed for normality before they were compared between 
cases and controls. The most up to date definition of MetS was used 
to identify a participant as having MetS and phenotypic characteristics 
alongside medication use were used to identify whether participants 
qualified for each variable [8]. The criteria used to determine whether 
an individual had MetS included any 3 or more of the following: 
a) Waist measurement of ≥102 cm in men and ≥88 cm in women; 
b) Triglycerides ≥150 mg/dL (1.7 mmol/L) or the use of any lipid 
controlling medication; c) High density lipoproteins of <40 mg/dL (1.0 
mmol/L) in men and <50 mg/dL (1.3 mmol/L) in women; d) Systolic 
blood pressure ≥130 mmHg and/or diastolic blood pressure ≥85 mmHg 
and/or the use of any blood pressure controlling medications; e) Fasting 
plasma glucose ≥100 mg/dL (5.55 mmol/L) or the use of any diabetes 
controlling medications. We then compared the distribution of binary 
variables in cases and controls using Chi-Square test, non-normally 
distributed continuous data using Wilcox Test and normally distributed 
continuous variables using two sided t-test. A p-value of <0.05 was used 
to determine statistical significance. 
A crude logistic regression of each of the 46 whole plasma N-glycan 
traits against the binary outcome of MetS was run first. Then, two 
different adjusted models were run. First, a “baseline adjusted” model, 
which included only age, CRP levels and gender as confounding 
factors and second a “fully adjusted” model which included all of 
the previous alongside medication use, smoking status and familial 
relationships. P-values, odds ratios (ORs) and 95% confidence intervals 
were also reported. The false discovery rate (q) was calculated to adjust 
for multiple testing and q values of <0.05 were deemed statistically 
significant.
The ORCADES data set includes several family members and 
N-glycans are partly influenced by genetically coded enzymes, alongside 
it being common for families to share similar lifestyles. Thus, familial 
relationships of participants were also considered to be a potential 
confounding factor. Effect of heritability on N-glycans and MetS was 
controlled in the regression model using pedigree information. ASReml 
software was used to create an additive genetic relationship matrix from 
this pedigree. Two assumptions were made here in order to determine 
the correlation expected from additive genetic effects, including the 
assumption of normal modes of inheritance and that genetic effects 
were correlated.
In order to achieve results that were comparable with that reported 
in Lu et al. the analysis of correlation of 4 MetS components against 
17 derived glycan traits was conducted. MetS components included 
Body Mass Index (BMI), Systolic Blood Pressure (SBP), Diastolic Blood 
Pressure (DBP) and FPG. Correlation coefficients were calculated 
with the Spearman method being used for those characteristics with 
a non-normal distribution (age, BMI, SBP and FPG), and the Pearson 
method was used for parametric characteristics (DBP). P-values for 
these correlations were generated through linear regression. After this, 
the false discovery rate (FDR) method was used in order to adjust for 
multiple testing and values were generated for each of the correlation 
coefficients. Results were then compared to that of the analysis 
conducted by Lu et al.
Results
Characteristics of studied population for case-control analysis
In the case-control study section of this analysis, the Orcadian 
population analysed consisted of 2,039 individuals, of which 39.6% were 
male. Table 1 details the distribution of individual MetS components. It 
is evident that high blood pressure was the most common component of 
MetS, with 1030 individuals fitting the criteria for high blood pressure. 
The second most common component of MetS in this population 
was a large waist measurement, whilst fewer people were found to 
have abnormal lipids or FPG. According to pre-specified criteria, 564 
participants were found to have MetS. In addition, it was found that 
251 and 68 individuals had 4 and all 5 components respectively. As high 
BP was found to be so common within the population, it was noted 
that only 299 participants would be considered to have MetS if BP was 
ignored.
As indicated in Table 2, a higher proportion of females were found 
to have MetS (30.7% compared to 23%), with the prevalence of MetS in 
general being 27.7%. Alongside this, the average age of those with MetS 
was found to be higher. No difference was found between the groups 
for “current” smoking, however, it was found that those with MetS were 
more likely to have smoked in the past. Regarding medication use, it 
was evident that that those with MetS were more than twice as likely 
Characteristica
Normal/
Characteristic 
absent (%) 
Abnormalb/
Characteristic present 
(%)
Waist measurement (n=2,008) 1109 (55.2%) 899 (44.8%)
Triglycerides (n=2,081) 1550 (74.5%) 531 (25.5%)
HDL (n=2,077) 1605 (77.3%) 472 (22.7%)
BP (n=2,022) 992 (49.1%) 1030 (50.9%)
Glucose (n=2,079) 1568 (75.4%) 511 (24.6%)
MetS (At least 3 of the above) 
(n=2,039) 1475 (72.3%) 564 (27.7%)
MetS (4/5 components)
(n=2,039) 1788 (87.7%) 251 (12.3%)
MetS (5/5 components)
(n=2,039) 1971 (96.7%) 68 (3.3%)
aThe variation in examined population size (n) is due to missing data for certain 
characteristics for individuals
bCharacteristics were deemed “abnormal” if they fitted the criteria detailed by 
Alberti et al. [8]
Table 1: Distribution of MetS components within the ORCADES population.
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No MetS 
n=1475
MetSc 
n=564
Chi-
Square t-test
Men (n=807) (39.6%) 621 (77%) 186 (23%) 2.01E-04 -
Women (n=1,232) (60.4%) 854 (69.3%) 378 (30.7%) 2.01E-04 -
Age (years +/- SD) 52.00 (+/- 15.17)
56.39 (+/- 
15.04) -
2.60E-
09
CRP (mg/L +/- SD) 2.23 +/- 4.10 3.21 +/- 5.51 - 2.60E-04
“Current” Smoking 
(n=161) 115 (7.8%) 46 (8.2%) 0.95 -
“Ever” Smoking (n=756) 486 (32.9%) 270 (47.9%) 3.54E-09 -
Anti-inflammatory 
Medications (n=449) 221 (15.0%) 228 (40.4%) <2.2E-16 -
Hormonal Medications 
(n=117) 112 (7.6%) 5 (0.87%) 6.46E-09 -
 cInsufficient data was found in 116 participants to diagnose the MetS
Table 2: Baseline characteristics of the ORCADES population (n=2,155).
to be on an anti-inflammatory medication, whilst those on hormonal 
medication were less likely to have MetS. 
Analysis of glycan profiles in cases and controls
Table 3 details that 27 out of 46 glycan traits were found to be 
statistically significantly associated with MetS in the crude model after 
adjusting for multiple testing. On adjusting for the effect of CRP, age 
and gender, this number reduced to 24. The additional adjustment for 
smoking, medication use and familial relationships in the final model 
ensured that this number was further reduced to 21 significant traits. Of 
these 21 glycan traits, 6 were derived glycan measures including BADS, 
BAMS, FUC-C, A2, G0 and G4.
Of these 21 traits, 12 were found to be associated with an increased 
likelihood of having the MetS (GP1, GP2, GP9, DG1, DG2, DG5, 
DG10, monosialylated, disialylated, BADS, A2 and G0), whilst 9 were 
associated with a decreased likelihood of having the MetS (GP5, GP6, 
GP8, GP15, DG6, DG13, BAMS, FUC-C and G4). The magnitude of 
effect of the identified positive associations ranged from an odds ratio 
(OR) of 1.14 (95% CI 1.02, 1.27) for DG5, to an OR of 1.66 (95% CI 
1.48, 1.86) for DG10. Regarding negative associations, the magnitude 
of effect varied from 0.88 (95% CI 0.79, 0.98) for G4 to 0.62 (95% CI 
0.55, 0.70) for GP8.
Analysis of correlation of glycan traits with individual MetS 
components
Tables 4-7 display a comparison of the results from the ORCADES 
analysis compared to that found in Lu et al (2011). As displayed in 
Table 4, five glycan traits were found to be significantly correlated 
with BMI in all three populations, including G3, TRI (triantennary), 
FUC-C (core fucose), monosialylated and trisialylated glycans. Of 
these, monosialylated glycans and FUC-C were found to have negative 
correlations in each three populations, whilst the others had positive 
correlations in all three populations. Table 5 shows that 5 glycan 
components were also found to be significantly correlated with SBP in 
each of the three studied populations. G0 (0.27 (1.2E-15)), A2 (0.19 
(6.1E-14)) and trisialylated glycans (0.066 (0.047)) were found to be 
positively correlated with SBP, whilst G2 (-0.20 (1.2E-15)) and FUC-C 
(-0.21 (1.2E-15)) were found to be negatively correlated with SBP in 
each of the three populations. Alongside the direction of effect, it can 
be noted that the magnitude of effect was also similar across each of 
the studies. For example, G2 was found to have a correlation coefficient 
of -0.200, -0.270 and -0.202 in the ORCADES, Chinese and Croatian 
studies respectively. As shown in Table 6, no glycan traits were found 
to be significantly correlated with DBP across all three populations. 
However, 5 traits were found to be significant in ORCADES alongside 
being statistically significant in only one of the other populations. Table 
7 displays that the level of disialylated glycans and core-fucosylated 
glycans were the only glycan traits found to be significantly correlated 
with FPG in all three studies. Each study found that level of core 
fucosylated glycans had a negative correlation coefficient, whilst 
disialylated glycans had a positive correlation coefficient. As displayed 
throughout Tables 4-7, the magnitude of effect showed a tendency to 
be greater in the Chinese study. However, as glycan profiles were rank 
transformed prior to analysis in the Orcadian population only, the 
magnitude of the correlation coefficients are not directly comparable.
Table 8 presents a summary of the findings from the analysis in 
the ORCADES data set only, including q-values after the adjustment 
for multiple testing. It is evident, that of the 36 statistically significant 
correlations between glycan components and BMI, SBP, DBP and 
FPG found in the ORCADES population, 12 were found to also be 
statistically significant in both the Chinese and Croatian populations. 
Of these, 5 were with BMI, 5 with DBP and 2 with FPG. It is interesting 
to note that the direction of the correlation coefficients was the same 
across the studies for each of these 12 consistent associations. Evidently, 
core fucosylated glycans were found to be significantly correlated with 
age, BMI, SBP and FPG across all three studies, making it the most 
replicated finding. 
Discussion
The aim of this project was to investigate the association between 
human plasma N-Glycan structures and MetS. In the first section of this 
analysis, many glycan traits were found to be significantly associated 
with having the MetS in the ORCADES population. Such associations 
were particularly evident regarding core fucosylated glycans and the 
level of sialylation of glycans.
In the second section of this analysis, some statistically significant 
associations between glycan trait and the components of BMI, BP and 
FPG which had been identified in Chinese and Croatian populations 
were found to be replicated in the Orcadian population. Results which 
were not found to be replicated across these groups may be population 
specific associations, reflecting differences in environment, lifestyle or 
genetics. 
Alterations in glycosylation patterns can reflect the metabolic state 
of the cells from which they originate, thus such glycomic alterations 
may arise from several different combinations of pathological pathways 
of MetS. These results perhaps shed light on important glycomic 
alterations underlying the inflammatory processes of the macrovascular 
problems associated with this syndrome. As vascular inflammation is an 
early stage in the development of atherosclerosis, glycomic information 
such as this may prove useful as a clinical marker for identifying patients 
who have a greater long term risk of cardiovascular events. There are 
many other potential explanations for the glycomic changes observed. 
For example, the increased levels of G0, A2 and trisialylated N-glycans 
found to be associated with high SBP in all three examined populations 
may reflect a reduced bioavailability of nitric oxide or may also portray 
the effects of an increased level of angiotensin II.
Changes in the level of core fucosylation of plasma N-glycans was 
the only N-glycan trait found to be associated with more than one 
individual MetS component (BMI, SBP and FPG), as well as those with 
MetS as a whole. It has been suggested that core fucosylated glycans 
could have a role in the regulation of cell growth and metabolism 
through epidermal growth factor receptor (EGFR), PI-3K-dependent 
insulin signaling pathways and Transforming Growth Factor beta 
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Glycan trait Crude OR (95% CI) n=1959 p q
Baseline adjusted     
OR (95% CI) n=1915 p q
Fully adjusted  OR 
(95% CI) n=1833 p q 
GP1d 1.26 (1.14-1.39) 8.4E-06 2.4E-05 1.25 (1.13-1.39) 1.7E-05 5.0E-05 1.16 (1.04-1.30) 0.0068 0.018d
GP2d 1.32 (1.20-1.46) 5.6E-08 2.0E-07 1.30 (1.18-1.45) 5.4E-07 1.9E-06 1.23 (1.10-1.38) 2.3E-04 9.7E-04d
GP3 1.12 (1.02-1.24) 0.021 0.035 1.14 (1.02-1.26) 0.015 0.032 1.10 (0.99-1.23) 0.075 0.14
GP4 0.84 (0.76-0.93) 0.00068 0.0016 0.89 (0.80-0.99) 0.026 0.050 0.95 (0.85-1.06) 0.35 0.43
GP5d 0.84 (0.76-0.93) 0.00066 0.0016 0.85 (0.77-0.95) 0.0028 0.0076 0.87 (0.78-0.97) 0.012 0.029 d
GP6d 0.60 (0.54-0.66) 2.0E-16 3.1E-15 0.64 (0.57-0.71) 1.9E-15 2.9E-14 0.72(0.64-0.81) 8.4E-08 7.2E-07 d
GP7 0.90 (0.82-1.00) 0.043 0.064 0.89 (0.80-0.99) 0.029 0.052 0.89 (0.80-0.99) 0.032 0.068
GP8d 0.53 (0.48-0.59) 2.0E-16 3.1E-15 0.56 (0.50-0.62) 2.0E-16 4.6E-15 0.62 (0.55-0.70) 6.8E-14 1.6E-12 d
GP9d 1.38 (1.25-1.53) 5.3E-10 2.4E-09 1.36 (1.22-1.50) 1.0E-08 5.7E-08 1.32 (1.18-1.47) 1.3E-06 7.7E-06 d
GP10 1.01 (0.92-1.12) 0.83 0.91 1.01 (0.91-1.12) 0.83 0.83 1.00 (0.90-1.12) 0.95 0.95
GP11 1.86 (1.06-3.49) 0.038 0.058 0.96 (0.87-1.06) 0.44 0.55 0.96 (0.86-1.07) 0.45 0.51
GP12 1.00 (0.90-1.10) 0.95 0.96 0.97 (0.88-1.07) 0.56 0.62 0.95 (0.85-1.06) 0.36 0.43
GP13 0.95 (0.86-1.05) 0.28 0.37 0.93 (0.84-1.03) 0.16 0.24 0.92 (0.83-1.03) 0.15 0.22
dq<0.05; statistically significant correlation coefficient in the “Fully adjusted” model
Table 3a: Results from regression analysis of glycan components against MetS.
Glycan trait Crude OR (95% CI) n=1959 p q
Baseline adjusted 
OR (95% CI) n=1915 p q
Fully adjusted  OR 
(95% CI) n=1833 p q 
GP14 1.15 (1.04-1.26) 0.0071 0.013 1.10 (0.99-1.22) 0.068 0.11 1.03 (0.92-1.14) 0.66 0.71
GP15d 0.90 (0.82-1.00) 0.047 0.068 0.88 (0.79-0.97) 0.012 0.025 0.84 (0.75-0.93) 0.0014 0.0048d
GP16 1.00 (0.91-1.11) 0.96 0.96 0.97 (0.87-1.07) 0.51 0.59 0.90 (0.81-1.01) 0.072 0.14
DG1d 1.30 (1.17-1.43) 5.6E-07 1.7E-06 1.29 (1.16-1.43) 2.1E-06 6.4E-06 1.18(1.06-1.32) 0.0035 0.011d
DG2d 1.33 (1.21-1.48) 2.8E-08 1.1E-07 1.32 (1.18-1.46) 3.3E-07 1.3E-06 1.21 (1.08-1.36) 7.4E-04 0.0026d
DG3 0.96 (0.87-1.06) 0.40 0.48 0.96 (0.87-1.07) 0.49 0.58 0.92 (0.82-1.02) 0.12 0.19
DG4 0.82 (0.74-0.91) 0.00015 3.9E-04 0.87 (0.79-0.97) 0.011 0.024 0.91 (0.81-1.01) 0.086 0.15
DG5d 1.16 (1.05-1.28) 0.0038 0.0073 1.14 (1.03-1.27) 0.010 0.024 1.14 (1.02-1.27) 0.017 0.040 d
DG6d 0.68 (0.61-0.75) 2.7E-13 2.0E-12 0.73 (0.66-0.81) 1.1E-08 5.8E-08 0.80 (0.72-0.90) 1.4E-04 7.3E-04d
DG7 0.96 (0.87-1.06) 0.38 0.48 0.96 (0.87-1.06) 0.44 0.55 0.94 (0.85-1.05) 0.28 0.40
DG8 1.01 (0.91-1.11) 0.87 0.94 0.98 (0.87-1.09) 0.73 0.75 1.02 (0.91-1.14) 0.73 0.74
DG9 1.16 (1.05-1.28) 0.0035 0.0070 1.12 (1.01-1.24) 0.034 0.071 1.05 (0.94-1.17) 0.43 0.51
DG10d 1.75 (1.57-1.95) 2.0E-16 3.1E-15 1.70 (1.52-1.90) 2.0E-16 4.6E-15 1.66 (1.48-1.86) 3.0E-17 1.4E-15d
dq<0.05; statistically significant correlation coefficient in the “Fully adjusted” model 
Table 3b: Results from regression analysis of glycan components against MetS.
Glycan trait Crude OR (95% CI) n=1959 p q
Baseline adjusted     
OR (95% CI)          
n=1915
p q Fully adjusted  OR (95% CI) n=1833 p q 
DG10d 1.75 (1.57-1.95) 2.0E-16 3.1E-15 1.70 (1.52-1.90) 2.0E-16 4.6E-15 1.66 (1.48-1.86) 3.0E-17 1.4E-15d
DG11 1.00 (0.91-1.11) 0.94 0.96 0.96 (0.87-1.07) 0.48 0.58 0.93 (0.84-1.04) 0.19 0.28
DG12 1.11 (1.01-1.23) 0.035 0.056 1.06 (0.95-1.17) 0.30 0.40 0.97 (0.87-1.08) 0.57 0.64
DG13d 0.95 (0.86-1.05) 0.32 0.41 0.91 (0.82-1.01) 0.073 0.12 0.87 (0.78-0.97) 0.010 0.025d
Monosialod 0.71 (0.64-0.78) 2.5E-11 1.4E-10 0.72 (0.65-0.80) 1.6E-09 1.1E-08 1.49 (1.33-1.67) 8.2E-12 1.3E-10d
Disialod 1.47 (1.33-1.63) 1.9E-13 1.7E-12 1.50 (1.35-1.67) 7.5E-14 8.7E-13 1.49 (1.33-1.67) 8.2E-12 1.3E-10d
Trisialo 1.16 (1.05-1.28) 0.0034 0.0070 1.11 (1.00-1.24) 0.043 0.073 1.10 (0.99-1.23) 0.087 0.15
Tetrasialo 1.01 (0.92-1.12) 0.82 0.91 0.97 (0.88-1.08) 0.61 0.66 0.95 (0.85-1.06) 0.32 0.41
BA 0.90 (0.81-0.99) 0.031 0.051 0.95 (0.86-1.06) 0.35 0.46 0.98 (0.88-1.09) 0.69 0.72
BAMSd 0.71 (0.64-0.78) 4.5E-11 2.3E-10 0.71 (0.64-0.79) 2.5E-10 1.9E-09 0.73 (0.65-0.82) 6.8E-08 7.2E-07d
BADSd 1.48 (1.33-1.64) 1.8E-13 1.7E-12 1.42 (1.28-1.58) 1.2E-10 1.1E-09 1.35 (1.21-1.51) 2.5E-07 1.6E-06d
TRIA 1.15 (1.04-1.27) 0.0061 0.011 1.09 (0.98-1.21) 0.10 0.16 1.09 (0.97-1.22) 0.13 0.21
TA 1.03 (0.93-1.14) 0.54 0.62 0.97 (0.88-1.08) 0.61 0.66 0.92 (0.82-1.02) 0.11 0.18
dq<0.05; statistically significant correlation coefficient in the “Fully adjusted” model
Table 3c: Results from regression analysis of glycan components against MetS.
(TGF-beta) [19]. As discussed above, impairment of such pathways has 
leads to a blockade of the anti-inflammatory and vasodilatory effects of 
insulin, thus contributing to the vascular dysfunction characteristic of 
T2DM [20]. Our results agreed with this hypothesis, as those with MetS 
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Glycan Trait Crude OR (95% CI) n=1959 p q
Baseline adjusted OR 
(95% CI)n=1915 p q
Fully adjusted  OR 
(95% CI) n=1833 p q 
FUC-Cd 0.70 (0.63-0.77) 8.1E-12 5.3E-11 0.75 (0.67-0.83) 7.3E-08 3.1E-07 0.81 (0.72-0.90) 1.7E-04 7.8E-04 d
FUC-A 0.93 (0.84-1.02) 0.13 0.19 0.93 (0.84-1.03) 0.19 0.26 0.85 (0.62-1.17) 0.31 0.41
A2d 1.30 (1.18-1.44) 2.9E-07 9.6E-07 1.29 (1.16-1.43) 1.4E-06 4.7E-06 1.18 (1.06-1.33) 0.0038 0.011d
G0d 1.36 (1.23-1.51) 2.9E-09 1.2E-08 1.34 (1.21-1.49) 4.7E-08 2.2E-07 1.23 (1.10-1.38) 3.4E-04 1.3E-03d
G1 0.84 (0.76-0.93) 0.00082 0.0018 0.89 (0.80-0.98) 0.022 0.045 0.89 (0.80-1.00) 0.046 0.091
G2 0.83 (0.75-0.91) 0.00019 4.8E-04 0.87 (0.78-0.97) 0.0098 0.024 0.94 (0.84-1.05) 0.30 0.40
G3 1.06 (0.96-1.17) 0.28 0.37 1.02 (0.92-1.13) 0.74 0.75 0.98 (0.87-1.09) 0.65 0.71
G4d 0.96 (0.87-1.07) 0.48 0.56 0.93 (0.84-1.03) 0.17 0.24 0.88 (0.79-0.98) 0.019 0.042d
dq<0.05; statistically significant correlation coefficient in the “Fully adjusted” model
Table 3d: Results from regression analysis of glycan components against MetS.
Glycan trait
ORCADES 
BMI
(n=2,039)
r
Chinese
BMI
(n=212)
r
Croatian
BMI
(n=520)
r
ORCADES
BMI
p
ORCADES
BMI
q
Chinese
BMI
p
Croatian
BMI
p
G0 0.083 0.021 0.19 0.004 0.0052e 0.76 <0.001f
G1 -0.11 -0.104 -0.10 2.0 E-07 5.6 E-07e 0.13 0.023f
G2 -0.082 -0.117 -0.089 0.00068 0.0013e 0.090 0.044f
G3 0.053 0.260 0.11 0.0034 0.0048e <0.001f 0.013f
G4 -0.014 -0.076 -0.055 0.88 0.88 0.27 0.21
A2 0.047 0.081 0.058 0.33 0.37 0.24 0.20
BA -0.092 -0.227 -0.076 2.7 E-05 5.7 E-05e <0.001f 0.089
TRI 0.13 0.250 0.11 3.0 E-08 1.0 E-07e <0.001f 0.018f
TA 0.0044 0.027 -0.022 0.50 0.53 0.70 0.63
FUC-C -0.15 -0.234 -0.11 2.7 E-09 1.2 E-08e <0.001f 0.011f
FUC-A -0.074 -0.151 -0.046 0.0020 0.0031e 0.028 f 0.30
BAMS -0.15 0.026 -0.22 2.7 E-09 1.2 E-08e 0.71 <0.001f
BADS -0.074 -0.045 0.25 0.0020 0.0031e 0.52 <0.001f
Monosialylated -0.16 -0.344 -0.14 1.0 E-11 1.8 E-10e <0.001f 0.001f
Disialylated 0.15 0.210 0.072 2.1 E-10 1.8 E-09e 0.0020f 0.10
Trisialylated 0.12 0.292 0.12 6.0 E-07 1.5 E-06e <0.001f 0.0070f
Tetrasialylated -0.040 -0.009 -0.039 0.056 0.068 0.89 0.38
eq<0.05 in the ORCADES population; statistically significant correlation coefficient
fp<0.05 in the Chinese and Croatian populations; statistically significant correlation coefficient
Table 4: Correlation analysis of N-glycan traits with BMI.
were more likely to have lower levels of plasma core fucosylated glycans. 
Thus, in light of the results of this study, level of core fucosylation 
of plasma N-glycans could be used as a marker for early vascular 
dysfunction.
Careful consideration was given to the effect of confounding factors 
in this analysis and the difference in results between the crude and both 
adjusted models, Tables 3a-3d illustrate the importance of adjusting 
models in this way. In spite of this, it is clear that there are many other 
factors, including complex biochemical characteristics that may have 
had a confounding effect on these results. In addition, although age 
was adjusted for in the regression models, the relationship between 
glycans, age and MetS may have been illustrated more effectively had 
we stratified the population by age. It is also important to note that the 
use of a pedigree file alone in the adjustment for family relationships 
ensures that it was assumed that immediate family members share the 
same percentage of DNA. In reality, this is not the case and this could 
have been improved had the adjustment been based on genetic data.
The differential medical treatment of cases and controls was 
evidently an important source of bias in this analysis. The ORCADES 
reported the use of many medications, which were used in the 
identification of cases and adjustment for confounding in this analysis. 
However it is understood that the reporting of medication use in this 
data set was not comprehensive, thus it is possible a misclassification 
bias was introduced in this way.
As portrayed in the above tables, several participants had missing 
data for certain characteristics, thus were removed from the analysis 
at different stages. This was most evident in the results of the fully 
adjusted regression model, as the package used to adjust for familial 
relationships (ASReml) required all participants with any missing 
glycan data to be removed prior to analysis (322 removed). Alongside 
reducing the power of this analysis if the missing values were in some 
way related, this list-wise deletion may have ensured the results of this 
analysis were biased.
 In the second section of this analysis there were evident procedural 
differences between the three included studies, which may have limited 
the comparability of their results. Alongside this, when comparing 
results regarding MetS between populations it is important to 
remember that the qualifying limits for MetS vary between different 
populations. In order to tackle this, we investigated the correlation of 
glycans with individual MetS components and identified differences 
in this between the populations. However, such an analysis does not 
illustrate the higher susceptibility that certain groups have to the 
negative pathophysiological consequences of the MetS. Also, it was not 
possible to directly compare the magnitude of calculated correlation 
coefficients between these studies, as the ORCADES values were the 
only results to be rank transformed prior to analysis. Furthermore, the 
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Glycan trait
ORCADES
SBP
(n=2,039)
r
Chinese 
SBP 
(n=212)
r
Croatian
SBP
(n=520)
r
ORCADES
SBP
p
ORCADES
SBP
q
Chinese 
SBP
p
Croatian
SBP
P
G0 0.27 0.19 0.31 2.0 E-16 1.2 E-15e 0.0080f <0.001f
G1 -0.0035 -0.023 0.037 0.88 0.88 0.75 0.40
G2 -0.20 -0.27 -0.20 2.0 E-16 1.2 E-15e <0.001f <0.001f
G3 0.019 0.26 0.043 0.77 0.82 <0.001f 0.33
G4 -0.0033 -0.013 0.015 0.57 0.64 0.86 0.74
A2 0.19 0.23 0.16 1.8 E-14 6.1 E-14e 0.0020f <0.001f
BA -0.067 -0.20 -0.054 0.028 0.047e 0.0070f 0.23
TRI 0.063 0.21 0.049 0.033 0.051 0.0040f 0.27
TA 0.060 0.088 0.063 0.046 0.066 0.23 0.16
FUC-C -0.21 -0.29 -0.099 2.7 E-16 1.2 E-15e <0.001f 0.026f
FUC-A 0.060 -0.019 -0.037 0.015 0.033e 0.80 0.41
BAMS -0.21 -0.097 -0.075 2.7 E-16 1.2 E-15 0.19 0.096
BADS 0.060 0.11 0.16 0.015 0.033e 0.12 <0.001 f
Monosialylated -0.081 -0.37 -0.055 0.0058 0.016e <0.001f 0.21
Disialylated 0.070 0.23 -0.049 0.052 0.068 0.0010f 0.27
Trisialylated 0.066 0.30 0.090 0.028 0.047e <0.001f 0.042f
Tetrasialylated 0.025 -0.021 -0.034 0.19 0.23 0.775 0.44
eq<0.05 in the ORCADES population; statistically significant correlation coefficient 
fp<0.05 in the Chinese and Croatian populations; statistically significant correlation coefficient
Table 5: Correlation analysis of N-glycan traits with SBP.
Glycan trait
ORCADES
DBP
r
Chinese
DBP
r
Croatian
DBP
r
ORCADES
DBP
p
ORCADES
DBP
q
Chinese
DBP
p
Croatian
DBP
p
G0 0.11 0.037 0.27 3.7 E-06 2.1 E-05e 0.61 <0.001f
G1 -0.037 -0.096 0.084 0.11 0.16 0.19 0.057
G2 -0.095 -0.13 -0.14 3.2 E-05 1.4 E-04e 0.072 0.001f
G3 -0.0017 0.21 0.003 0.94 0.95 0.004f 0.94
G4 -0.023 -0.014 -0.048 0.32 0.36 0.85 0.28
A2 0.081 0.053 0.14 3.5 E-4 0.0012 e 0.47 0.0020f
BA -0.053 -0.19 0.018 0.020 0.049e 0.0090f 0.68
TRI 0.064 0.21 -0.012 4.8 E-3 0.014e 0.0050f 0.79
TA 0.026 0.060 -0.025 0.26 0.31 0.42 0.57
FUC-C -0.11 -0.18 -0.023 2.7 E-16 4.7 E-15e 0.013f 0.61
FUC-A 0.041 -0.068 -0.070 0.075 0.13 0.30 0.12
BAMS -0.11 -0.12 -0.086 3.5 E-06 2.1 E-05e 0.10 0.056
BADS 0.041 0.12 0.12 0.075 0.13 0.092 0.010f
Monosialylated -0.040 -0.28 -0.060 0.079 0.13 <0.001f 0.17
Disialylated 0.033 0.19 0.025 0.14 0.18 0.0080f 0.56
Trisialylated 0.033 0.22 0.076 0.14 0.18 0.0020f 0.083
Tetrasialylated 0.0014 -0.10 -0.15 0.95 0.95 0.17 0.0010f
eq<0.05 in the ORCADES population; statistically significant correlation coefficient
fp<0.05 in the Chinese and Croatian populations; statistically significant correlation coefficient
Table 6: Correlation analysis of N-glycan traits with DB.
analysis of only 3 components of MetS ensured that the extrapolation of 
these results to consider MetS as a whole is limited. It is also important 
to note that it is not possible to ascertain the direction of causality 
of these observed associations and it is possible that these findings 
are a consequence of altered metabolism in the MetS. Further study 
with the use of large cohort populations will be essential in order to 
investigate the causal relationship of these associations. Once this has 
been determined, the clinical utility of glycans as biomarkers for risk 
stratification can be determined. 
In addition to these limitations, it is important to recognize that 
as the glycan analysis technique used relies on relative quantification, 
it is not possible to determine whether an identified increase in one 
glycan trait is not solely due to a decrease in others, or an increase in 
the plasma level of the protein to which it is bound. Thus limiting the 
conclusions we can draw from such an analysis. In order to overcome 
this, future glycomic studies can instead isolate and examination of the 
N-glycan profile of specific proteins.
Conclusion
Our results demonstrate that SBP, BMI, FPG and MetS as a whole 
are associated with an alteration in human N-glycosylation patterns. 
Our results show that such alterations vary by component, thus it is 
likely that such alterations reflect a complex array of the metabolic 
changes found in this syndrome. Such information may prove to be 
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G1 0.032 -0.12 -0.10 0.020 0.058 0.11 0.019f
G2 -0.020 -0.17 -0.049 0.68 0.75 0.022f 0.27
G3 0.0081 0.26 0.12 0.75 0.75 <0.001f 0.0070f
G4 -0.025 0.067 -0.025 0.31 0.44 0.37 0.57
A2 0.16 0.11 0.13 6.9 E-04 2.3 E-03e 0.15 0.0050f
BA 0.065 -0.25 -0.087 0.72 0.75 0.0010f 0.051
TRI -0.040 0.26 0.12 0.60 0.72 <0.001f 0.009f
TA -0.092 0.11 -0.0010 0.057 0.12 0.12 0.99
FUC-C -0.16 -0.21 -0.11 2.6 E-09 2.2 E-08e 0.004f 0.011f
FUC-A -0.00093 -0.033 -0.054 0.10 0.17 0.659 0.22
BAMS -0.16 0.018 -0.15 2.6 E-09 2.2 E-08e 0.810 <0.001f
BADS -0.00094 0.012 0.18 0.10 0.17 0.868 <0.001f
monosialylated -0.021 -0.29 -0.12 0.052 0.12 <0.001f 0.0050f
disialylated 0.10 0.16 0.097 5.3 E-05 2.3 E-04e 0.029f 0.028f
trisialylated -0.043 0.24 0.10 0.35 0.45 0.001f 0.021f
tetrasialylated -0.038 0.0010 -0.037 0.21 0.32 0.99 0.41
eq<0.05 in the ORCADES population; statistically significant correlation coefficient
fp<0.05 in the Chinese and Croatian populations; statistically significant correlation coefficient
Table 7: Correlation analysis of N-glycan traits with FPG.
Glycan trait
BMI
r (q)
n=2,011
SBP
r (q)
n=2,006
DBP
r (q)
n=2,004
FPG
r (q)
n=2,078
G0 0.083 (0.0052) 0.27 (1.2E-15) 0.11(2.1E-05) 0.18 (1.7E-05)
G1 -0.11 (5.6E-07) -0.0035 (0.88) -0.037 (0.16) 0.032 (0.058)
G2 -0.082 (0.0013) -0.20 (1.2E-15) -0.095 (1.4E-04) -0.020 (0.75)
G3 0.053 (0.0048) 0.019 (0.82) -0.0017 (0.95) 0.0081 (0.75)
G4 -0.014 (0.88) -0.0033 (0.64) -0.023 (0.36) -0.025 (0.44)
A2 0.047 (0.37) 0.19 (6.1E-14) 0.081 (0.0012) 0.16 (2.3E-03)
BA -0.092 (5.7E-05) -0.067 (0.047) -0.053 (0.049) 0.065 (0.75)
TRI 0.13 (1.0E-07) 0.063 (0.051) 0.064 (0.014) -0.040 (0.72)
TA 0.0044 (0.53) 0.060 (0.066) 0.026 (0.31) -0.092 (0.12)
FUC-C -0.15 (1.2E-08) -0.21 (1.2E-15) -0.11(4.7E-15) -0.16 (2.2E-08)
FUC-A -0.074 (0.0031) 0.060 (0.033) 0.041 (0.13) -0.00093 (0.17)
BAMS -0.15 (1.2E-08) -0.21 (1.2E-15) -0.11 (2.1E-05) -0.16 (2.2E-08)
BADS -0.074 (0.0031) 0.060 (0.033) 0.041 (0.13) -0.00094 (0.17)
Monosialo -0.16 (1.8E-10) -0.081 (0.016) -0.040 (0.13) -0.021 (0.12)
Disialo 0.15 (1.8E-09) 0.070 (0.068) 0.033 (0.18) 0.10 (2.3E-04)
Trisialo 0.12 (1.5E-06) 0.066 (0.047) 0.033 (0.18) -0.043 (0.45)
Tetrasialo -0.040 (0.068) 0.025 (0.23) 0.0014 (0.95) -0.038 (0.32)
Presented numerical results are that of the ORCADES study population
                   Indicates the result was replicated across all three studies
                   Indicates the result was significant in ORCADES and Croatian studies only
                   Indicates the result was significant in ORCADES and Chinese studies only
                   Indicates the result was significant in Chinese and Croatian studies only
Table 8: Comparison of correlation analysis results across the three populations. 
useful as a risk stratifying biomarker, perhaps identifying those for 
whom metabolic alterations are more advanced. Such information may 
prove useful in the clinical setting, ensuring that those with subclinical 
levels of inflammation and insulin resistance can be identified and 
targeted for preventative treatments. Alongside this, these results 
highlight that further investigation of the importance of the core 
fucosylation of proteins in the state of insulin resistance is required. 
Future research in this area should involve the N-glycan analysis of 
individual glycoproteins (e.g. IgG) in cohort study populations.
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